|
KMID : 1141720150030020005
|
|
폐쇄성폐질환
2015 Volume.3 No. 2 p.5 ~ p.5
|
|
|
|
|
Kim Yee-Hyung
|
|
|
Abstract
|
|
|
|
Current chronic obstructive pulmonary disease (COPD) guidelines recommend using inhaled corticosteroids (ICS) in patients whose airflow limitation is severe or exacerbations are frequent. This is based upon evidences that ICS reduce the frequency of exacerbations, and improve quality of life and lung function, when ICS are used along with long-acting ß2-agonists (LABA). However, studies about prescribing patterns have demonstrated ICS are used more frequently outside current guideline recommendations. There is a lack of evidence that ICS slow decline rate of lung function. Additionally, the evidences of increased risk of pneumonia due to ICS are growing. A combination of LABA with long-acting anti-muscarinic receptor antagonists (LAMA) have potential to be an alternative to ICS/LABA. It is certain that the paradigm in treatment of COPD is shifting according to the results from recent large scale studies. We think there is need to clarify the role of ICS in treatment of COPD.
|
|
|
KEYWORD
|
|
|
Chronic obstructive lung disease, Treatment, Inhaled corticosteroids
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|